Robert L. Ternik, Ph.D., R.Ph., is senior research advisor, Small Molecule Design and Development, at Eli Lilly and Company. He is responsible for creating and implementing human-centered design capability for Lilly’s small molecule drug product portfolio. He is a member of the Pediatric Working Group of the IQ Consortium.
Julia Gao, Ph.D., is an associate director at Bristol-Myers Squibb Company, where she is responsible for commercial oral product development for BMS’s small molecule portfolio. He is a member of the Pediatric Working Group of the IQ Consortium.
Robert Ju, Ph.D., is an associate director at Abbvie, where his group is responsible for formulation development of AbbVie’s small molecule portfolio. He chairs the Pediatric Working Group of the IQ Consortium.
Globally, the design and development of pediatric drug products has significantly lagged behind the development of drug products for adult populations. The lag is largely attributable to a combination of economic factors, therapeutic and bioethical factors, and the challenges associated with conducting robust pediatric clinical trials with the innate diversity of the pediatric population. This lag has greatly affected pediatric patients by limiting the availability of beneficial and potentially life-saving medicines and requiring health care professionals to use medicines studied and designed for adults in children. Continue reading